| Literature DB >> 23110324 |
Yasunori Ueda1, Chisato Mizutani, Yasuhito Nannya, Mineo Kurokawa, Sumiko Kobayashi, Jin Takeuchi, Hideto Tamura, Kiyoyuki Ogata, Kazuo Dan, Hirohiko Shibayama, Yuzuru Kanakura, Keiko Niimi, Ko Sasaki, Masato Watanabe, Nobuhiko Emi, Masanao Teramura, Toshiko Motoji, Michiko Kida, Kensuke Usuki, Satoru Takada, Toru Sakura, Yoshikazu Ito, Kazuma Ohyashiki, Hiroyasu Ogawa, Takahiro Suzuki, Keiya Ozawa, Kiyotoshi Imai, Masaharu Kasai, Tomoko Hata, Yasushi Miyazaki, Yasuyoshi Morita, Akihisa Kanamaru, Akira Matsuda, Kaoru Tohyama, Daisuke Koga, Hiroya Tamaki, Kinuko Mitani, Tomoki Naoe, Haruo Sugiyama, Fumimaro Takaku.
Abstract
A study to evaluate WT1 mRNA expression levels in peripheral blood (PB) and bone marrow aspirate (BM) was conducted in 172 patients, including 115 with myelodysplastic syndromes (MDS), in Japan. The level of WT1 mRNA expression was evaluated according to the French-American-British (FAB) and World Health Organization (WHO) classifications (2001, 2008) and using the International Prognostic Scoring System and the WHO Prognostic Scoring System scales. WT1 mRNA expression levels in PB and BM were well correlated (r = 0.85), and they tended to increase with disease stage progression and in those at higher risk of leukemic transformation. WT1 mRNA expression can be a useful marker for the diagnosis and risk evaluation of MDS.Entities:
Mesh：
Substances：
Year: 2012 PMID： 23110324 DOI： 10.3109/10428194.2012.745074
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022